



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q79659

Jaakko PARKKINEN

Appln. No.: 10/585,745

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Unknown

Filed: July 12, 2006

For: PROCESS FOR THE MANUFACTURE OF VIRUS SAFE IMMUNOGLOBULIN

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/585,745

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant submits the following explanation: The non patent literature document by KRUNEN (Chemie en Techniek, 1970, 25, 193-196) is cited on page 14 in the specification of the present application.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Respectfully submitted,



Gordon Kit
Registration No. 30,764

Date: February 5, 2007

Substitute for Form 1449 A & B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/585,745
Confirmation Number	Unknown
Filing Date	July 12, 2006
First Named Inventor	Jaakko PARKKINEN
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	Q79659

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 5,096,637	A	03-17-1992	DILEO, et al.
		US 6,307,028	B1	10-23-2001	LEBING, et al.
		US 5,886,154	A	03-23-1999	LEBING, et al.
		US 6,251,860	B1	06-26-2001	PARKKINEN, et al.
		US 6,326,473	B1	12-04-2001	PARKKINEN, et al.
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		WO	96/35710	A1	11-14-1996	SUOMEN PUNAINEN RISTI VERIPALVELU	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		HAYAKAWA, et al., "Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin", British Journal of Haematology, 2002, 118, 1187-1189	
		KNEZEVIC-MARAMICA and KRUSKALL, "Intravenous immune globulins: an update for clinicians", Transfusion, 2003, Vol. 43, 1460-1480	
		ONCLEY, et al., "The Separation of the Antibodies, Isoagglutinins, Prothrombin, Plasminogen and β_1 -Lipoprotein into Subfractions of Human Plasma", J. Am. Chem. Soc., 1949, 71, 541-550	
		SCHMIDT, et al., "Parvovirus B19 DNA in plasma pools and plasma derivatives", Vox Sanguinis, 2001, 81, 228-235	
		HIRVONEN, et al., "A sensitive enzyme immunoassay for the measurement of low concentrations of IgA", Journal of Immunological Methods, 1993, 163, 59-65	
		SKOOG, "Determination of Polyethylene Glycols 4000 and 6000 in Plasma Protein Preparations", Vox Sang., 1979, 37, 345-349	
		KRUNEN, "Chemie en bloed Het optimal gebruik van menselijk bloed", Chemie en Techniek 1970, 25, 193-196	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.